Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Porphyria cutanea tarda

G H Elder1

  • 1Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff, UK.

Seminars in Liver Disease
|March 28, 1998
PubMed
Summary
This summary is machine-generated.

Porphyria cutanea tarda (PCT) is a skin disease caused by reduced uroporphyrinogen decarboxylase (UROD) activity. Its development is linked to liver injury, iron overload, and genetic factors influencing UROD inactivation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking economic hardship to adolescent aggression.

Journal of youth and adolescence·2013
Same author

Molecular epidemiology of erythropoietic protoporphyria in the U.K.

The British journal of dermatology·2010
Same author

A homozygous mutation in the ferrochelatase gene underlies erythropoietic protoporphyria associated with palmar keratoderma--reply.

The British journal of dermatology·2009
Same author

The molecular genetics of erythropoietic protoporphyria.

Cellular and molecular biology (Noisy-le-Grand, France)·2009
Same author

Serum 25-hydroxyvitamin D in erythropoietic protoporphyria.

The British journal of dermatology·2008
Same author

Late presentation of erythropoietic protoporphyria: case report and genetic analysis of family members.

The British journal of dermatology·2007
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Dermatology

Background:

  • Porphyria cutanea tarda (PCT) is a prevalent skin disorder stemming from diminished uroporphyrinogen decarboxylase (UROD) activity.
  • PCT manifests in sporadic (type I) and familial (type II) forms, with type I involving liver-specific UROD deficiency and type II linked to autosomal dominant UROD gene mutations with incomplete penetrance.
  • Environmental factors like porphyrogenic chemicals, alcohol abuse, hepatitis C infection, and estrogen exposure can trigger clinically overt PCT, particularly when liver cell injury occurs.

Purpose of the Study:

  • To elucidate the biochemical mechanisms underlying UROD inactivation in Porphyria cutanea tarda.
  • To investigate the role of hepatic iron overload in PCT pathogenesis and remission/relapse cycles.
  • To explore the genetic basis of susceptibility to PCT, particularly concerning genes regulating UROD inactivation pathways.

Related Experiment Videos

Main Methods:

  • Biochemical assays to assess UROD activity and inactivation processes.
  • Analysis of patient data correlating clinical presentation with genetic factors and environmental exposures.
  • Investigation of iron metabolism and its impact on UROD function in liver cells.

Main Results:

  • UROD inactivation in PCT targets its catalytic site and is dependent on iron and heme precursors.
  • Hepatic iron overload is a common feature, with iron depletion leading to remission and repletion causing relapse.
  • Genetic factors influencing the UROD inactivation process may determine individual susceptibility to PCT following liver injury.

Conclusions:

  • PCT pathogenesis involves iron-dependent inactivation of hepatic UROD, exacerbated by liver injury and specific environmental factors.
  • Iron homeostasis plays a critical role in managing PCT, offering therapeutic targets for remission.
  • Genetic predisposition, interacting with environmental triggers and iron status, significantly influences PCT development.